Clinical Trial

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

Study acronym: WaveSpan-008

Recruiting Phase 1/2

Summary

Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nodes. The lymphatic system is part of the immune system. In this study, researchers want to learn if MK-1045 can treat FL and DLBCL. MK-1045 is a study treatment that is an immunotherapy, which helps the immune system fight cancer. The goals of this study are to learn how safe MK-1045 is and if people tolerate it. Researchers also want to see if FL and DLBCL respond (the cancer gets smaller or goes away) to treatment.

Protocol Amendment History 11 changes

notable Trial sites expanded: 30 -> 34 locations 2026-08-15

critical Primary endpoint(s) modified 2026-08-08

notable Enrollment increased: 200 -> 280 participants 2026-08-08

notable Trial sites expanded: 22 -> 30 locations 2026-08-08

notable Trial sites expanded: 18 -> 21 locations 2026-07-19

notable Trial sites expanded: 13 -> 18 locations 2026-07-11

notable Trial sites expanded: 8 -> 13 locations 2026-07-03

notable Trial sites expanded: 4 -> 8 locations 2026-06-30

notable Primary completion pushed: 2030-01-20 -> 2030-07-01 2026-06-24

minor Completion pushed: 2030-10-21 -> 2031-04-01 2026-06-24

critical Recruitment opened 2026-05-16

Trial Details

NCT Number	NCT07519772
Lead Sponsor	Merck Sharp & Dohme LLC
Conditions	Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Enrollment	280 participants
Start Date	2026-05-03
Primary Completion	2030-07-01 (estimated)
Study Completion	2031-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-14